Hospitalization for heart failure occurred in 8.6% of patients in the empagliflozin group and 11.8% patients in the placebo group (hazard ratio, 0.71; 95% CI, 0.60 to 0.83)

number needed to treat [NNT] = 32 per 26 months

 
But the drug company did a great job of writting the paper so you think there is mortality benefit

https://www.nejm.org/doi/full/10.1056/NEJMoa2107038